drugset
drugset / Trial / NCT01270880

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

NCT01270880 ↗

Phase 2 Completed 18 enrolled Barbara Ann Karmanos Cancer Institute National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090 works in treating patients with metastatic hormone-resistant prostate cancer previously treated with docetaxel-based chemotherapy

Timeline

Start
2011-01
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganetespib Small molecule — Intravenous

Indications

hormone-resistant prostate carcinoma prostate adenocarcinoma